Gender | Baseline | 4Â weeks after the 1st dose of PZQ | 4Â weeks after the 2nd dose of PZQ | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | AM/10Â ml | No assessed | No cured | Failure cases | CR | AM/10Â ml | ERR | No Assessed | No cured | No of Failure | CR | AM/10Â ml | ERR | |
Female | 73 | 103.04 | 50 | 43 | 7 | 86.0 | 2.08 | 80 | 3 | 3 | 0 | 100 | 0 | 100 |
Male | 47 | 99.13 | 41 | 34 | 7 | 82.9 | 3.61 | 64 | 4 | 2 | 2 | 50 | 22 | 78 |